The utility of the cystatin C test in diagnosing kidney disease

12. May 2021 | 3 min read

The utility of the cystatin C test in diagnosing kidney disease

Webinar about cystatin C as an alternative to creatinine

In this exciting webinar a multidisciplinary panel of experts examine the clinical utility of the cystatin C test in diagnosing kidney disease. The aim of this discussion was to educate healthcare practitioners on the cystatin C testing option and help them effectively communicate the benefits of the test to their patients.

Content of the webinar:

  • Importance of Estimated GFR - Josef Coresh, MD, PhD Johns Hopkins University
  • The Epidemiological Argument for Cystatin C and Impact of GFR Staging on Medication Eligibility and Dosing - Michael Shlipak, MD, MPH San Francisco VA Health Care System and University of California, San Francisco
  • Clinical Case Examples - Michelle Estrella, MD, MHS San Francisco VA Health Care System and University of California, San Francisco
  • Barriers to widespread use of cystatin C and how to overcome them - Amy Karger, MD, PhD University of Minnesota


The webinar is sponsored by Gentian Diagnostics.

 

The Gentian Cystatin C Immunoassay

The Gentian Cystatin C Immunoassay is an open channel turbidimetric test for quantitative determination of cystatin C in human serum and plasma.

  • FDA510(k) cleared and CE-marked and IVDR certified
  • Developed and manufactured by Gentian
  • Manufactured according to ISO 13485:2016

 

Order here:

For more information or ordering cystatin C, please fill out the form below:

 

 

 

You may also read


Canine CRP customer story - First-line test to detect inflammation

Jan 29, 2026

Canine CRP customer story - First-line test to detect inflammation

Gentian Canine CRP continuously available since 2013 The Gentian Canine CRP immunoassay, available since..

Cystatin C, GFR and Shrunken Pore Syndrome: Insights from Dr. A. Grubb

Jan 20, 2026

Cystatin C, GFR and Shrunken Pore Syndrome: Insights from Dr. A. Grubb

Expanding the understanding of kidney disease Shrunken Pore Syndrome (SPS) and Selective Glomerular..

GCAL® Calprotectin - From insights to impact - January 2026

Jan 13, 2026

GCAL® Calprotectin - From insights to impact - January 2026

Continuing the GCAL® journey: Building on 2025, moving into 2026 Over the past year, interest in circulating..